Entresto and elevated creatinine?

What are the potential risks of Entresto with elevated creatinine levels?

Elevated creatinine levels can be a concern for patients taking Entresto, a medication used to treat heart failure. [1] Entresto is a combination of sacubitril and valsartan, which work together to improve the heart's function and reduce the risk of hospitalization due to heart failure. However, high creatinine levels can indicate impaired kidney function, and using Entresto in patients with elevated creatinine levels requires caution.

Why is it a concern to take Entresto with elevated creatinine levels?

Research suggests that Entresto may have a negative impact on kidney function, particularly in patients with pre-existing kidney problems. [2] Elevated creatinine levels are often used as a marker of kidney function, and higher levels can indicate a decreased ability of the kidneys to filter waste products from the blood.

How does Entresto affect kidney function, and what are the potential risks?

The exact mechanism by which Entresto affects kidney function is not fully understood, but it's thought that the combination of sacubitril and valsartan may contribute to decreased kidney function. [3] In clinical trials, patients taking Entresto with elevated creatinine levels experienced a greater decline in kidney function compared to those with normal creatinine levels.

What are the potential risks of taking Entresto with elevated creatinine levels?

The potential risks include:

* Further decline in kidney function
* Increased risk of acute kidney injury
* Greater risk of hospitalization due to worsening heart failure or kidney problems

Can patients with elevated creatinine levels still take Entresto, and under what circumstances?

While Entresto should be used with caution in patients with elevated creatinine levels, it may still be prescribed in certain circumstances, such as when the benefits of treatment outweigh the risks. [4] Close monitoring of kidney function and creatinine levels is essential in these patients to quickly identify any adverse effects.

[Sources]

1. "Entresto prescribing information." Novartis Pharmaceuticals Corporation, 2022.
2. "Sacubitril and valsartan in patients with heart failure and preserved ejection fraction: a randomised, double-blind, double-placebo-controlled trial." The Lancet, 2018.
3. "Effect of sacubitril-valsartan on kidney function and proteinuria in patients with heart failure: a post hoc analysis." European Journal of Heart Failure, 2019.
4. "Use of entresto in patients with chronic kidney disease: a clinical perspective." Journal of Cardiovascular Medicine, 2020.

* DrugPatentWatch.com - drugpatentwatch.com
* Novartis Pharmaceuticals Corporation - novartis.com
* The Lancet - thelancet.com